Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871728 | 0.87 | ALDH1A1 (0.41) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL10015377 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL236431 | 0.77 | TSHR (0.56) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL16841649 | 0.76 | TSHR (0.42) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL13907969 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL5091798 | 0.75 | TSHR (0.44) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL14769217 | 0.75 | TSHR (0.52) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL7773775 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL2719070 | 0.75 | ALDH1A1 (0.43) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR | |
| SCHEMBL8577573 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2RAB9AALDH1A1ALOX12TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133763-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023247729-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247731-A1 | ROR1/PTK7 BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2023-12-28 | — | — | WO | disclosed |
| EP-4262987-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230241072-A1 | ANTHRACYCLINE DERIVATIVES | ALMAC DISCOVERY LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| WO-2022129622-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-3986473-A1 | ANTHRACYCLINE DERIVATIVES | Almac Discovery Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254640-A1 | ANTHRACYCLINE DERIVATIVES | ALMAC DISCOVERY LIMITED (GB) | 2020-12-24 | — | — | WO | disclosed |
| CN-106163559-A | anti-HER 3 antibody-drug conjugates | 第三共株式会社 | 2016-11-23 | — | — | CN | disclosed |
| CN-104583775-B | Assay tag | 维瓦克塔有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-102046203-A | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of aids | PASTEUR INSTITUT | 2011-05-04 | — | — | CN | disclosed |
| CN-101072581-A | Therapeutic agents with reduced toxicity | GENENTECH INC (US) | 2007-11-14 | — | — | CN | disclosed |
| CN-1309416-C | Novel pharmaceutical composition | HOFFMANN LA ROCHE (CH) | 2007-04-11 | — | — | CN | disclosed |
| CN-1901934-A | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory bowel disease | HOFFMANN LA ROCHE (CH) | 2007-01-24 | — | — | CN | disclosed |
| US-7152462-B2 | Topography and recognition imaging atomic force microscope and method of operation | AGILENT TECHNOLOGIES, INC (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060016251-A1 | Topography and recognition imaging atomic force microscope and method of operation | KEYSIGHT TECHNOLOGIES, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6952952-B2 | Topography and recognition imaging atomic force microscope and method of operation | MOLECULAR IMAGING CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040129064-A1 | For detecting interactions between a probe and a sensed agent on a scanned surface | KEYSIGHT TECHNOLOGIES, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004042741-A2 | TOPOGRAPHY AND RECOGNITION IMAGING ATOMIC FORCE MICROSCOPE AND METHOD OF OPERATION | MOLECULAR IMAGING CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| CN-1429116-A | Novel pharmaceutical composition | HOFFMANN LA ROCHE (CH) | 2003-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241072-A1 | ANTHRACYCLINE DERIVATIVES | TOP2A, TOP2B, BCL6 | SMN1; SMN2 4427/4885RAB9A 1006/4885ALDH1A1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.